Tempus

Tempus is an American biotechnology company that provides data and AI services for the healthcare industry. The company collects genomic data from patients, organizes it, and provides insights with the help of machine learning. It has 3.5+ million patient records in its oncology dataset. Tempus' products and services are used in oncology, neurology, life sciences and infectious disease research to provide patients with personalized, targeted therapies.

Tempus offers services both directly to patients and through physicians. The company is headquartered in Chicago, Illinois.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
Share Price
Growth Capital20 Oct, 2022
***
***
***
Series G10 Dec, 2020
***
***
***
Series G13 Mar, 2020
***
***
***
Series F30 May, 2019
***
***
***
Series E29 Aug, 2018
***
***
***
Series D20 Mar, 2018
***
***
***
Series C25 Sep, 2017
***
***
***
Series B17 Apr, 2017
***
***
***
Series B22 Nov, 2016
***
***
***
Series B20 Jun, 2016
***
***
***
Series A21 Sep, 2015
***
***
***

*** - To view the data, please log into your account or create a new one.

News related to Tempus118

Filter by
Sort by
Tempus
Apr 22, 2024Show on chart

TIME Reception: ASCO 2024 - Tempus

TIME Reception: ASCO 2024 - Tempus...

Tempushttps://www.tempus.com/events/time-reception-asco-2024/
Tempus
Apr 11, 2024Show on chart

Tempus Evening Reception: ASCO 2024 - Tempus

Tempus Evening Reception: ASCO 2024 - Tempus...

Tempushttps://www.tempus.com/events/tempus-evening-reception-asco-2024/
Tempus
Apr 8, 2024Show on chart

Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2- Directed Antibody-Drug Conjugates in Several Tumor Types - Tempus

Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting. The abstract, titled “Analysis of HER2 prevalence by RNA expression across solid tumors,” found that by correlatin...

Tempushttps://www.tempus.com/news/tempus-releases-new-data-at-aacr-showcasing-ways-to-analyze-multimodal-data-to-highlight-potential-therapeutic-routes-for-her2-directed-antibody-drug-conjugates-in-several-tumor-types/
Tempus
Apr 8, 2024Show on chart

Tempus Releases New Data at AACR Showcasing Ways to Analyze ...

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare....

https://www.morningstar.com/news/business-wire/20240408433828/tempus-releases-new-data-at-aacr-showcasing-ways-to-analyze-multimodal-data-to-highlight-potential-therapeutic-routes-for-her2-directed-antibody-drug-conjugates-in-several-tumor-types
Tempus
Apr 8, 2024Show on chart

Tempus Releases New Data at AACR Showcasing Ways to Analyze ...

CHICAGO, April 08, 2024--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the ...

https://finance.yahoo.com/news/tempus-releases-data-aacr-showcasing-133000550.html
Show more (113)

Investors8

New Enterprise AssociatesNew Enterprise Associates
RevolutionRevolution
T. Rowe PriceT. Rowe Price
Baillie GiffordBaillie Gifford
Novo HoldingsNovo Holdings
Franklin TempletonFranklin Templeton
GoogleGoogle
Franklin Templeton InvestmentsFranklin Templeton Investments

Tempus Twitter